Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2082832 | Drug Discovery Today: Therapeutic Strategies | 2013 | 6 Pages |
Abstract
Alzheimer's disease (AD) induces a widespread pathological extracellular accumulation of beta-amyloid (Aβ) peptides that affects cortical networks underpinning cognitive functions. This is related to abnormal functional and effective brain connectivity as revealed by graph markers of resting-state eyes-closed electroencephalographic (EEG) rhythms. Here we revised EEG studies in mild cognitive impairment and AD subjects showing that these markers are promising network disease endpoints for basic research and AD drug discovery.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Claudio Babiloni, Francesco Infarinato, Antonio I. Triggiani, Roberta Lizio, Claudio Del Percio, Nicola Marzano, Jill C. Richardson,